CBD activates liver enzymes, but CBG shows minimal effects

This study examined how two cannabis compounds, cannabidiol (CBD) and cannabigerol (CBG), interact with the aryl hydrocarbon receptor (AhR) pathway in human cells. The AhR pathway is important because it controls the production of cytochrome P450 enzymes (CYP1A), which are responsible for breaking down drugs and compounds in the body. Researchers tested these cannabinoids in three different cell types—liver cells, primary hepatocytes, and skin cells—to understand their effects at the molecular level.

CBD proved to be a potent activator of the AhR pathway, significantly increasing both the gene expression and protein levels of CYP1A enzymes in all tested cell models. However, the researchers discovered something surprising: while CBD increased the amount of CYP1A proteins in cells, it only slightly boosted the actual enzymatic activity of these proteins. This distinction matters because it suggests that increasing protein levels doesn't automatically translate to increased metabolic capacity. In contrast, CBG had minimal effects on the AhR pathway, showing negligible activation at the receptor level and producing only weak increases in CYP1A mRNA that didn't result in meaningful changes to protein levels or enzyme activity.

The practical implications are significant for cannabis users and researchers. Since CBD is known to activate drug-metabolizing enzymes, this could affect how the body processes other medications or cannabinoids—potentially leading to drug interactions. CBG, however, appears to have minimal impact on this pathway, suggesting it may be a safer option for those taking multiple medications. The researchers emphasize that these findings are from laboratory studies and that the real-world effects in living organisms remain unknown, highlighting the need for further research before drawing conclusions about clinical use.